# A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

> **NCT06300320** · PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** TQ05105 tablets

## Key facts

- **NCT ID:** NCT06300320
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2025-10
- **Final completion:** 2026-04
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06300320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06300320, "A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06300320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*